167 related articles for article (PubMed ID: 27547781)
1. Physiological role of receptor activator nuclear factor-kB (RANK) in denervation-induced muscle atrophy and dysfunction.
Dufresne SS; Boulanger-Piette A; Bossé S; Frenette J
Receptors Clin Investig; 2016 May; 3(2):e13231-e13236. PubMed ID: 27547781
[TBL] [Abstract][Full Text] [Related]
2. Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.
Dufresne SS; Boulanger-Piette A; Bossé S; Argaw A; Hamoudi D; Marcadet L; Gamu D; Fajardo VA; Yagita H; Penninger JM; Russell Tupling A; Frenette J
Acta Neuropathol Commun; 2018 Apr; 6(1):31. PubMed ID: 29699580
[TBL] [Abstract][Full Text] [Related]
3. Muscle RANK is a key regulator of Ca2+ storage, SERCA activity, and function of fast-twitch skeletal muscles.
Dufresne SS; Dumont NA; Boulanger-Piette A; Fajardo VA; Gamu D; Kake-Guena SA; David RO; Bouchard P; Lavergne É; Penninger JM; Pape PC; Tupling AR; Frenette J
Am J Physiol Cell Physiol; 2016 Apr; 310(8):C663-72. PubMed ID: 26825123
[TBL] [Abstract][Full Text] [Related]
4. Muscle weakness and selective muscle atrophy in osteoprotegerin-deficient mice.
Hamoudi D; Bouredji Z; Marcadet L; Yagita H; Landry LB; Argaw A; Frenette J
Hum Mol Genet; 2020 Feb; 29(3):483-494. PubMed ID: 31943048
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin protects against muscular dystrophy.
Dufresne SS; Dumont NA; Bouchard P; Lavergne É; Penninger JM; Frenette J
Am J Pathol; 2015 Apr; 185(4):920-6. PubMed ID: 25708645
[TBL] [Abstract][Full Text] [Related]
6. Corticotropin releasing factor 2 receptor agonists reduce the denervation-induced loss of rat skeletal muscle mass and force and increase non-atrophying skeletal muscle mass and force.
Hinkle RT; Donnelly E; Cody DB; Bauer MB; Sheldon RJ; Isfort RJ
J Muscle Res Cell Motil; 2004; 25(7):539-47. PubMed ID: 15711884
[TBL] [Abstract][Full Text] [Related]
7. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
Vega D; Maalouf NM; Sakhaee K
J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
[TBL] [Abstract][Full Text] [Related]
8. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
9. Effects of chronic electrical stimulation on contractile properties of long-term denervated rat skeletal muscle.
al-Amood WS; Lewis DM; Schmalbruch H
J Physiol; 1991 Sep; 441():243-56. PubMed ID: 1816374
[TBL] [Abstract][Full Text] [Related]
10. Delayed denervation-induced muscle atrophy in
Zhang M; Chen M; Li Y; Rao M; Wang D; Wang Z; Zhang L; Yin P; Tang P
Front Physiol; 2023; 14():1127474. PubMed ID: 36909232
[TBL] [Abstract][Full Text] [Related]
11. "Fast" and "slow" muscle fibres in hindlimb muscles of adult rats regenerate from intrinsically different satellite cells.
Kalhovde JM; Jerkovic R; Sefland I; Cordonnier C; Calabria E; Schiaffino S; Lømo T
J Physiol; 2005 Feb; 562(Pt 3):847-57. PubMed ID: 15564285
[TBL] [Abstract][Full Text] [Related]
12. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
Hofbauer LC; Heufelder AE
J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
[TBL] [Abstract][Full Text] [Related]
13. Sarcoplasmic reticulum Ca2+ pump expression in denervated skeletal muscle.
Schulte L; Peters D; Taylor J; Navarro J; Kandarian S
Am J Physiol; 1994 Aug; 267(2 Pt 1):C617-22. PubMed ID: 8074194
[TBL] [Abstract][Full Text] [Related]
14. Changes in some troponin and insulin-like growth factor messenger ribonucleic acids in regenerating and denervated skeletal muscles.
Krishan K; Dhoot GK
J Muscle Res Cell Motil; 1996 Oct; 17(5):513-21. PubMed ID: 8906619
[TBL] [Abstract][Full Text] [Related]
15. Effects of chronic stimulation on the size and speed of long-term denervated and innervated rat fast and slow skeletal muscles.
Hennig R; Lømo T
Acta Physiol Scand; 1987 May; 130(1):115-31. PubMed ID: 3591384
[TBL] [Abstract][Full Text] [Related]
16. The Roles of RANK/RANKL/OPG in Cardiac, Skeletal, and Smooth Muscles in Health and Disease.
Marcadet L; Bouredji Z; Argaw A; Frenette J
Front Cell Dev Biol; 2022; 10():903657. PubMed ID: 35693934
[TBL] [Abstract][Full Text] [Related]
17. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
Clézardin P
Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
[TBL] [Abstract][Full Text] [Related]
18. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
Wittrant Y; Théoleyre S; Chipoy C; Padrines M; Blanchard F; Heymann D; Rédini F
Biochim Biophys Acta; 2004 Sep; 1704(2):49-57. PubMed ID: 15363860
[TBL] [Abstract][Full Text] [Related]
19. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
Ikeda T; Utsuyama M; Hirokawa K
J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
[TBL] [Abstract][Full Text] [Related]
20. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
